Bausch + Lomb (NYSE:BLCO) Research Coverage Started at Cowen

Cowen initiated coverage on shares of Bausch + Lomb (NYSE:BLCOGet Rating) in a research note issued to investors on Wednesday, The Fly reports. The brokerage issued an outperform rating and a $35.00 price objective on the stock.

Separately, Cowen assumed coverage on shares of Bausch + Lomb in a report on Wednesday. They issued an outperform rating and a $35.00 price target on the stock.

Shares of BLCO stock opened at $17.72 on Wednesday. Bausch + Lomb has a 1 year low of $16.01 and a 1 year high of $20.20.

Bausch + Lomb Company Profile (Get Rating)

Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R).

Read More

The Fly logo

Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with's FREE daily email newsletter.